Literature DB >> 16204152

Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia.

Andreas Greinacher, Petra Eichler, Theresia Lietz, Theodore E Warkentin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16204152     DOI: 10.1182/blood-2005-05-1824

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Induction of anti-PF4/heparin antibodies after arthroplasty for rheumatic diseases.

Authors:  Kiyoshi Migita; Tomoyuki Asano; Shuzo Sato; Satoru Motokawa
Journal:  Fukushima J Med Sci       Date:  2018-04-07

Review 3.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally
Journal:  Blood       Date:  2017-04-17       Impact factor: 22.113

4.  Treatment outcomes of heparin-induced thrombocytopenia in subarachnoid hemorrhage patients: a 4-year, retrospective single-center review.

Authors:  Scott T Benken; Eljim P Tesoro; Keri S Kim; Jeffrey J Mucksavage
Journal:  Neurocrit Care       Date:  2012-10       Impact factor: 3.210

5.  Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.

Authors:  Theodore E Warkentin; Richard J Cook; Victor J Marder; Jo-Ann I Sheppard; Jane C Moore; Bengt I Eriksson; Andreas Greinacher; John G Kelton
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

6.  Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery.

Authors:  Seiji Bito; Shigeki Miyata; Kiyoshi Migita; Mashio Nakamura; Kazuhito Shinohara; Tomotaro Sato; Takeharu Tonai; Motoyuki Shimizu; Yasuhiro Shibata; Kazuhiko Kishi; Chikara Kubota; Shinnosuke Nakahara; Toshihito Mori; Kazuo Ikeda; Shusuke Ota; Takeshi Minamizaki; Shigeru Yamada; Naofumi Shiota; Masataka Kamei; Satoru Motokawa
Journal:  Blood       Date:  2015-12-09       Impact factor: 22.113

7.  Heparin-platelet factor 4 antibodies in intensive care patients: an observational seroprevalence study.

Authors:  Robert L Levine; Georgene W Hergenroeder; John L Francis; Charles C Miller; Marcie J Hursting
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

Review 8.  Heparin-induced thrombocytopenia in the ICU: an overview.

Authors:  Yasser Sakr
Journal:  Crit Care       Date:  2011-03-22       Impact factor: 9.097

9.  Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.

Authors:  M Margaret Prechel; Jeanine M Walenga
Journal:  Thromb J       Date:  2013-04-05

10.  Spontaneous heparin-induced thrombocytopenia syndrome presenting as bilateral adrenal infarction after knee arthroplasty.

Authors:  Elysha A VanderVeer; Raymond P Torbiak; Ally Ph Prebtani; Theodore E Warkentin
Journal:  BMJ Case Rep       Date:  2019-12-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.